Erasca, Inc. Stock Price, News & Analysis

Erasca, Inc. (Nasdaq: ERAS) reported its Q1 2022 financials, highlighting a cash position of $421.8 million expected to support operations into H2 2024. The company continues to progress its pipeline, with initial Phase 1b data for ERAS-007 and ERAS-601 expected in H2 2022, alongside an IND filing for ERAS-3490. R&D expenses rose significantly to $27.4 million, impacting net loss, which increased to $36.5 million or $(0.31) per share compared to last year. Encouraging preclinical and clinical developments were presented at the AACR Annual Meeting.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Bank of America Securities 2022 Healthcare Conference. CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a virtual fireside chat on May 10, 2022, at 1:20 p.m. PT. They will also hold one-on-one investor meetings. A live webcast will be available on the Bank of America website, with an archived replay accessible until August 10, 2022. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer.

Erasca has appointed Jean Liu, currently chief legal officer at Seagen, to its board of directors and audit committee. With over 20 years of experience in the biopharmaceutical sector, Liu has been instrumental in Seagen’s growth into a leading oncology company. Erasca aims to enhance its leadership team amid advancements in their RAS/MAPK pathway-focused pipeline, which targets various cancers. Liu’s expertise will support Erasca's mission to develop innovative therapies and address unmet needs in cancer treatment.

Erasca, Inc. (Nasdaq: ERAS) presented preclinical data from six poster presentations at the AACR Annual Meeting, showcasing three key candidates: ERAS-007, a selective ERK1/2 inhibitor; ERAS-601, a potent SHP2 inhibitor; and ERAS-3490, a CNS-penetrant KRAS G12C inhibitor. ERAS-007 shows promising activity in RAS/MAPK pathway-driven colorectal cancer, while ERAS-601 demonstrates anti-tumor activity in various models. ERAS-3490 targets CNS involvement in KRAS G12C mutant lung cancer. Initial clinical data for these candidates is expected in the near future, highlighting Erasca's commitment to RAS/MAPK-driven cancer therapies.

Erasca, Inc. (Nasdaq: ERAS) will host a virtual investor event on April 12, 2022, at 4:30 PM ET to discuss therapeutic opportunities in RAS/MAPK pathway-driven cancers, particularly gastrointestinal cancers. Key opinion leader Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center will present insights on unmet medical needs and Erasca's approach. The company will detail its pipeline and clinical development strategy targeting various cancers, including non-small cell lung cancer and hematologic malignancies. Registration and webcast details are available on the Erasca website.

Erasca reported Q4 2021 financial results, achieving clinical milestones ahead of schedule. The company has a strong cash position of $459 million as of December 31, 2021, up from $118.7 million a year prior. Major trial updates include ERAS-007, ERAS-601, and ERAS-801, with initial Phase 1b data expected in H2 2022. R&D expenses rose to $24.1 million for Q4 2021, reflecting increased clinical trial activity. The net loss improved to $30.5 million for Q4 2021 from $61.9 million in Q4 2020, indicating progress.

Erasca has announced a collaboration with Eli Lilly to evaluate ERAS-007, an ERK1/2 inhibitor, in a Phase 1b/2 HERKULES-3 trial for BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study will explore the combination of ERAS-007 with encorafenib and cetuximab, aiming to overcome resistance mechanisms linked to MAPK pathway reactivation. This approach is bolstered by preclinical data suggesting that ERAS-007 could enhance treatment efficacy. Approximately 180,000 patients with BRAF V600E mutations are affected globally, highlighting the potential market impact.

Erasca, Inc. (Nasdaq: ERAS) announced six poster presentations at the AACR Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The presentations will focus on key product candidates, including ERAS-007, a selective ERK1/2 inhibitor, and ERAS-601, a potent SHP2 inhibitor. Notably, ERAS-601 exhibits strong anti-tumor activity in RAS/MAPK-driven models. Details of the presentations, including dates, times, and locations, are outlined in the announcement. Erasca aims to advance therapies targeting RAS/MAPK pathway-driven cancers.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. The event, featuring CEO Jonathan E. Lim and CFO David M. Chacko, will take place in a virtual format on February 10, 2022, at 2:30 PM ET. The company will also engage in one-on-one investor meetings. A live webcast will be available at Erasca.com/events, with an archived replay for 30 days afterward. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.